Summary of Study ST002975

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001852. The data can be accessed directly via it's Project DOI: 10.21228/M8B424 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST002975
Study TitleMetabolomics Insights into Doxorubicin and 5-Fluorouracil Combination Therapy in Triple-Negative Breast Cancer: A Xenograft Model Study (Part 1)
Study TypeLC/MS/MS
Study SummaryBackground: Breast cancer is one of the most prevalent malignancies and a leading cause of death among women worldwide. Among its subtypes, triple-negative breast cancer (TNBC), which poses significant clinical challenges due to its aggressive behavior and limited treatment options. Aim: This study explored the effects of doxorubicin (DOX) and 5-fluorouracil (5-FU) as monotherapies and in combination on MDA-MB-231 xenograft model. Employing advanced metabolomics analysis, the study was designed to investigate molecular alterations triggered by these treatments. Methods: State-of-the-art metabolomics analysis using Ultra-high-performance liquid chromatography-electrospray ionization quadrupole time-of-flight mass spectrometry (UHPLC-ESI-QTOF-MS) was conducted including comprehensive plasma and tumor tissue sample profiling. Results: The study explored alterations induced by DOX, 5-FU, and their combination treatment. Each treatment group exhibited unique metabolic profiles in plasma and tumor analysis. Univariate and enrichment analyses identified alterations in metabolic pathways, including glycine and serine metabolism, spermidine and spermine biosynthesis, and purine and pyrimidine pathways. The combination of DOX and 5-FU significantly influenced plasma and tumor metabolites. The comprehensive metabolic profiling of both plasma and tumor samples shed light on the intricate changes within the tumor microenvironment and their systemic implications. Conclusion: The study findings offer insights into the metabolic vulnerabilities of TNBC in vivo induced by the studied chemotherapeutics. These findings highlight the involved metabolites and metabolic pathways in the response of MDA-MB-231 cells to DOX, 5-FU, and their combination which advance our understanding of TNBC treatment strategies, offering new possibilities for enhancing therapeutic outcomes.
Institute
Sharjah Institute for Medical Research
Last NameFacility
First NameCore
AddressM32, SIMR, College of Pharmacy, Health Sciences, University of Sharjah, Sharjah, UAE, Sharjah, 000, United Arab Emirates
Emailtims-tof@sharjah.ac.ae
Phone+971 6 5057656
Submit Date2023-11-08
Raw Data AvailableYes
Raw Data File Type(s)d
Analysis Type DetailLC-MS
Release Date2024-05-08
Release Version1
Core Facility Core Facility
https://dx.doi.org/10.21228/M8B424
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:


Factors:

Subject type: Mammal; Subject species: Mus musculus (Factor headings shown in green)

mb_sample_id local_sample_id Treatment
SA3231632B1-01-103855-fluorouracil
SA3231642A2-02-103845-fluorouracil
SA3231652A2-01-103835-fluorouracil
SA3231662B1-02-103865-fluorouracil
SA3231672B2-02-103885-fluorouracil
SA3231682B3-02-103905-fluorouracil
SA3231692B3-01-103895-fluorouracil
SA3231702A1-01-103815-fluorouracil
SA3231712B2-01-103875-fluorouracil
SA3231722A1-02-103825-fluorouracil
SA3231731A2-02-10371Doxorubicin
SA3231741A3-01-10372Doxorubicin
SA3231751A2-01-10370Doxorubicin
SA3231761A1-02-10369Doxorubicin
SA3231771A1-01-10368Doxorubicin
SA3231781B3-02-10379Doxorubicin
SA3231791A3-02-10373Doxorubicin
SA3231801B1-01-10374Doxorubicin
SA3231811B3-01-10378Doxorubicin
SA3231821B2-02-10377Doxorubicin
SA3231831B2-01-10376Doxorubicin
SA3231841B1-02-10375Doxorubicin
SA3231853B2-02-10399Doxorubicin + 5-fluorouracil
SA3231863B1-02-10397Doxorubicin + 5-fluorouracil
SA3231873B3-02-10401Doxorubicin + 5-fluorouracil
SA3231883B3-01-10400Doxorubicin + 5-fluorouracil
SA3231893B2-01-10398Doxorubicin + 5-fluorouracil
SA3231903B1-01-10396Doxorubicin + 5-fluorouracil
SA3231913A1-02-10393Doxorubicin + 5-fluorouracil
SA3231923A1-01-10392Doxorubicin + 5-fluorouracil
SA3231933A2-02-10395Doxorubicin + 5-fluorouracil
SA3231943A2-01-10394Doxorubicin + 5-fluorouracil
SA3231955A3-01-10420Negative Control
SA3231965A2-02-10419Negative Control
SA3231975A2-01-10418Negative Control
SA3231985A3-02-10421Negative Control
SA3231995A1-01-10416Negative Control
SA3232005B2-01-10424Negative Control
SA3232015B3-01-10426Negative Control
SA3232025B3-02-10427Negative Control
SA3232035B2-02-10425Negative Control
SA3232045A1-02-10417Negative Control
SA3232055B1-02-10423Negative Control
SA3232065B1-01-10422Negative Control
SA3232074B3-01-10413Positive Control
SA3232084A2-02-10406Positive Control
SA3232094A2-01-10405Positive Control
SA3232104A1-02-10404Positive Control
SA3232114A1-01-10403Positive Control
SA3232124A4-01-10407Positive Control
SA3232134A4-02-10408Positive Control
SA3232144B2-02-10412Positive Control
SA3232154B2-01-10411Positive Control
SA3232164B1-02-10410Positive Control
SA3232174B1-01-10409Positive Control
SA3232184B3-02-10414Positive Control
Showing results 1 to 56 of 56
  logo